B cells

[Molecular Cancer] The authors evaluate several of the ongoing and future directions of combining next-generation CRISPR-Cas9 gene editing with synthetic biology to optimize CAR T-cell therapy for future clinical trials toward the establishment of a new cancer treatment paradigm.

[Blood] The authors reported the first German real-world data on standard-of-care CAR-T cell therapies with the aim to explore risk factors associated with outcome.

[Cytometry Part A] Researchers developed a rapid semi-quantitative method for in situ imaging of bacteria and multiplex cell phenotypes on the same solid tumor tissue sections.

[Modern Pathology] Ten patients had a history of B cell malignancies, one each of myeloid neoplasm, breast or prostate cancer, and four others had underlying immune disorders. Most patients died, mostly of disease, with a median overall survival of 12.7 months.

[Molecular Therapy-Nucleic Acids] Initial in silico analysis predicted exons that can be skipped with minimal loss of neurofibromin function, which was confirmed with in vitro assessments utilizing an neurofibromatosis type 1 (Nf1) cDNA-based functional screening system.

[Journal of Translational Medicine] Researchers evaluated the functionality of mRNA-engineered dual-CAR NK-92 against tumor B cell lines and primary patient samples.